EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Baxter International's enterprise value is $22,485 Mil.
Baxter International's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $11,889 Mil. Therefore, Baxter International's EV-to-Revenue for today is 1.89.
The historical rank and industry rank for Baxter International's EV-to-Revenue or its related term are showing as below:
BAX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.86 Med: 3.43 Max: 4.9
Current: 1.89
During the past 13 years, the highest EV-to-Revenue of Baxter International was 4.90. The lowest was 1.86. And the median was 3.43.
BAX's EV-to-Revenue is ranked better than 67.11% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 3.23
vs BAX: 1.89
Baxter International EV-to-Revenue Historical Data
The historical data trend for Baxter International's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Baxter International's EV-to-Revenue
For the Medical Instruments & Supplies subindustry, Baxter International's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Baxter International's EV-to-Revenue falls into.
Baxter International's current Enterprise Value is $22,485 Mil.
Baxter International's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $11,889 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International (NYSE:BAX) EV-to-Revenue Explanation
Baxter International's share price for today is $28.25.
Baxter International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Baxter International's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BAX has been successfully added to your 